The goal is to address logistical challenges through planning, site selection and design services
Rapid Reshore & Development (RR&D), an alliance of three specialized firms working together to provide professional services for the life sciences and biopharmaceutical industries, has formed to address logistical challenges facing companies developing drugs, vaccines and medical devices.
The three firms—Facility Logix, EwingCole and Biggins Lacy Shapiro & Co.—intend to maximize efficiency, minimize risk and facilitate speed-to-market. The alliance represents a shift from transaction-driven service models to a holistic focus on client needs, integrating an interdisciplinary team customized for a variety of individual projects.
"Our rapidly changing world created a multitude of challenges and opportunities across all industries," said Jared Loos, PE, AIA, EwingCole's CEO. "However, few face logistical obstacles like the life sciences and manufacturing sectors, including biopharmaceuticals, medical devices, medical equipment and their respective supply chains. Our goal was to create an alliance that can collaboratively and succinctly support their needs from start to finish."
Life sciences and biopharmaceutical companies are pivoting to increase efficiency and capacity in record time, which requires quicker decision-making, identifying talent, retooling facilities, increasing capacity and shoring up resources.
According to its launch announcement, RR&D is approaching the speed-to-market process by aligning and accelerating all steps, including: Up-front planning and programming; scenario development and analysis; due diligence of talent market; new facility consideration and comparative costs; early conceptual designs; competitive real estate procurement, and full design/engineering and project management.
In related news, RR&D was selected this week by BrainStorm Cell Therapeutics Inc., a developer of autologous adult stem cell therapeutics, to expedite site selection and design services for a new manufacturing facility for NurOwn, a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis. RR&D will provide project management services throughout the project's lifecycle.
BrainStorm, which recently signed an agreement with Catalent Pharma Solutions to manufacture NurOwn at a scale large enough to meet potential commercial needs, intends to use the proposed 50,000-square-foot facility primarily for cell therapy production.
The facility is expected to contain manufacturing suites, complementary support and infrastructure, and the ability to expand the facility to 100,000 square feet to anticipate future programmatic needs.
Facility Logix, which specializes in the biotech industry, delivers new building solutions, enabling biotech companies to produce or house healthcare products. The company provides owners' representation, facilities planning, move and transition, as well as project and operational management implementation.
EwingCole, in practice for nearly 60 years, is a fully integrated architecture, engineering, interior design and planning firm with more than 400 professionals located in several US cities.
Biggins Lacy Shapiro & Co. features a multi-disciplinary team—attorneys, project finance and tax professionals, planners and engineers—for complex projects and portfolios through site selection, incentives and customized energy needs. Over the years, the firm has advised numerous pharmaceutical, gene therapy, biotechnology and consumer health companies.